SONM appears to have undergone a fundamental corporate transformation, changing its name from Sonim Technologies to DNA X while experiencing substantial revenue decline and severe cash deterioration.
The company has completely rebranded from a rugged device manufacturer serving enterprise clients to "DNA X" with unclear business focus, suggesting either a major strategic pivot or potential distress situation. The dramatic reduction in outstanding shares from 6.3 million to 1.5 million, combined with deteriorating financial metrics, indicates significant corporate restructuring that materially affects shareholder value.
The financial picture reveals a company under considerable stress, with revenue declining meaningfully to $58.3M while operating losses, though reduced, remain substantial at -$5.4M. The balance sheet shows critical liquidity concerns as cash dropped severely to just $1.3M from $5.3M, while accounts receivable collapsed by over 80%, suggesting either collection issues or a fundamental shift in business operations. Despite revenue contraction, inventory grew notably to $10.6M, creating an unfavorable working capital dynamic for a cash-constrained entity.
Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.
Receivables declined — improved collection efficiency or conservative revenue recognition.
Cash declined 75.6% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Inventory surged 63% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.
Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Net income grew 38.6% — bottom-line growth signals improving overall business health.
Revenue declined 37.7% — significant demand weakness or market share loss warrants investigation.
Liabilities increased 11.4% — monitor debt-to-equity ratio and interest coverage.
Asset base grew 10.5% — expansion through organic growth, acquisitions, or capital deployment.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →